Skip to main content
    M

    Medpace Holdings Inc (MEDP)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $648.20
    -5.74 (-0.88%)

    Market Cap: $18.29B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Medpace Holdings Inc (MEDP) Financials: Revenue, Profit and Cash Flow

    Updated Oct 21, 2026. Financial statements from company filings, amounts in US dollars.

    Medpace Holdings reported revenue of $2.53B for the fiscal year ended Dec 31, 2025, up 20.0% from the year before. That year, net income was $451.12M with a net margin of 17.8%, operating cash flow was $713.22M and free cash flow was $681.87M. The quarter ended Sep 30, 2026 had revenue of $716.00M and net income of $137.46M.

    Revenue and Margins

    The operating margin was 21.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $421.58M, a compound annual rate of 22.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.53B+20.0%100.0%21.1%17.8%
    Dec 2024$2.11B+11.8%100.0%21.2%19.2%
    Dec 2023$1.89B+29.2%100.0%17.9%15.0%
    Dec 2022$1.46B+27.8%100.0%19.1%16.8%
    Dec 2021$1.14B+23.4%100.0%17.4%15.9%
    Dec 2020$925.92M+7.5%100.0%18.0%15.7%
    Dec 2019$860.97M+22.2%100.0%14.8%11.7%
    Dec 2018$704.59M+61.5%30.6%14.3%10.4%
    Dec 2017$436.15M+3.5%51.4%14.9%9.0%
    Dec 2016$421.58MN/A87.9%12.5%3.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 11.6% from the year before. In the quarter ended Sep 2026, net income rose 23.7% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.53B$2.11B$1.89B$1.46B$1.14B$925.92M$860.97M$704.59M$436.15M$421.58M
    Cost of revenue$0$0$0$0$0$0$0$489.06M$211.77M$50.96M
    Gross profit$2.53B$2.11B$1.89B$1.46B$1.14B$925.92M$860.97M$215.53M$224.38M$370.62M
    Operating income$534.93M$446.87M$336.82M$278.70M$198.62M$167.04M$127.26M$101.05M$64.86M$52.49M
    Net income$451.12M$404.39M$282.81M$245.37M$181.85M$145.38M$100.44M$73.19M$39.12M$13.43M
    EBITDA$557.72M$480.18M$362.50M$308.11M$223.08M$187.05M$149.74M$133.81M$102.86M$112.76M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$716.00M$707.33M$706.60M$708.45M$659.90M$603.31M$558.57M$536.59M$533.32M$528.10M$511.04M$498.40M
    Gross profit$716.00M$707.33M$706.60M$708.45M$659.90M$603.31M$558.57M$536.59M$533.32M$528.10M$511.04M$498.40M
    Operating income$165.54M$146.82M$141.50M$153.27M$141.81M$126.33M$113.52M$125.38M$112.27M$105.15M$104.07M$87.32M
    Net income$137.46M$121.36M$123.87M$135.13M$111.14M$90.26M$114.59M$117.02M$96.43M$88.35M$102.59M$78.30M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $23.21M by $473.84M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.98B$2.10B$1.66B$1.35B$1.66B$1.39B$1.14B$1.00B$950.72M$979.11M
    Current assets$989.62M$1.03B$593.83M$333.96M$690.91M$473.65M$317.03M$177.74M$129.97M$133.25M
    Cash and equivalents$497.05M$669.44M$245.45M$28.27M$461.30M$277.77M$131.92M$0$26.48M$37.10M
    Total liabilities$1.52B$1.28B$1.10B$966.11M$707.01M$584.90M$416.79M$405.92M$447.19M$368.39M
    Short-term debt$23.21M$23.29M$292.96M$50.00M$159.29M$134.37M$109.25M$87.49M$16.50M$12.38M
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$79.72M$205.11M$151.27M
    Shareholder equity$459.07M$825.54M$558.95M$386.39M$952.93M$805.78M$726.28M$598.86M$503.53M$610.71M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$2.30B$2.06B$2.13B$1.98B$1.75B$1.57B$1.90B$2.10B$2.08B$1.92B$1.80B$1.66B
    Total liabilities$1.72B$1.62B$1.53B$1.52B$1.46B$1.40B$1.30B$1.28B$1.20B$1.16B$1.12B$1.10B
    Cash and equivalents$705.32M$502.69M$652.68M$497.05M$285.35M$46.33M$441.44M$669.44M$656.90M$510.89M$407.01M$245.45M
    Shareholder equity$584.94M$433.86M$598.31M$459.07M$293.64M$172.35M$593.61M$825.54M$881.44M$763.60M$671.54M$558.95M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 95.6% of operating cash flow. Share repurchases came to 134.5% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$713.22M$608.82M$433.37M$388.05M$263.33M$258.68M$201.87M$156.58M$97.39M$91.73M
    Capital expenditures$31.36M$36.55M$36.65M$36.88M$28.27M$31.34M$17.91M$16.02M$11.72M$13.54M
    Free cash flow$681.87M$572.27M$396.73M$351.17M$235.06M$227.34M$183.96M$140.56M$85.66M$78.19M
    Dividends paidN/AN/A$11.38M$22.07MN/AN/AN/AN/A$0$0
    Share repurchases$917.39M$169.87M$144.02M$847.85M$62.10M$98.27M$0$0$155.58M$2.72M
    Investing cash flow-$31.14M-$28.31M-$34.63M-$38.74M-$31.36M-$31.21M-$19.14M-$16.97M-$12.24M-$13.42M
    Financing cash flow-$860.39M-$154.01M-$182.64M-$775.77M-$44.45M-$82.28M-$73.92M-$141.58M-$97.83M-$58.01M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$216.60M$162.01M$151.79M$192.65M$246.21M$148.53M$125.84M$190.67M$149.07M$116.40M$152.68M$156.40M
    Capital expenditures$20.16M$23.91M$6.81M$4.54M$10.71M$6.11M$9.99M$7.64M$10.54M$12.87M$5.50M$9.99M
    Free cash flow$196.44M$138.10M$144.97M$188.12M$235.50M$142.41M$115.84M$183.02M$138.54M$103.53M$147.18M$146.41M
    Last 12 quarters

    Frequently Asked Questions About MEDP

    What is Medpace Holdings' annual revenue?

    Medpace Holdings reported revenue of $2.53B for the fiscal year ended Dec 31, 2025.

    How fast is Medpace Holdings' revenue growing?

    Revenue was up 20.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 20.1%.

    Is Medpace Holdings profitable?

    Yes. Medpace Holdings reported net income of $451.12M for the fiscal year ended Dec 31, 2025, with a net margin of 17.8%.

    How much free cash flow does MEDP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $713.22M minus capital expenditures of $31.36M produced free cash flow of $681.87M.

    How much debt does Medpace Holdings have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $23.21M and cash and equivalents of $497.05M.